Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Advanced Cancers

Advanced Cancers

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Advanced Cancers

12 trials tracked for Advanced Cancers: 3 in phase 3 or 4 and 1 with published results. The most-cited published study has 27 citations.

12Trials tracked
3Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 2 Phase 3 1 Phase 2 9
  1. Phase 4 Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain Completed · 27 cited
  2. Phase 4 Tolvaptan in Hyponatremic Cancer Patients Completed
  3. Phase 3 Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea Completed
  4. Phase 2 High Flow Oxygen and Bilevel Airway Pressure for Persistent Dyspnea in Patients With Advanced Cancer Completed
  5. Phase 2 Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma Completed
  6. Phase 2 Pilot Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Small Round Cell Tumor Completed
Show 6 more trials
  1. Phase 2 A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency Completed
  2. Phase 2 Dexamethasone Dyspnea Study Completed
  3. Phase 2 Fentanyl Pectin Nasal Spray (FNPS) for Exercise-Induced Breakthrough Dyspnea Completed
  4. Phase 2 The Effects of Thalidomide on Symptom Clusters Completed
  5. Phase 2 Fentanyl Buccal Tablets for Exercise Induced Breakthrough Dyspnea Completed
  6. Phase 2 Breakthrough Dyspnea Fentanyl Study in Cancer Patients Completed

Showing the 12 most-cited and recently-updated of 12 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Advanced Cancers: what the trials found

Fentanyl Nasal Spray has demonstrated non-inferiority to intravenous opioids in reducing Numeric Rating Scale (NRS) pain intensity scores at one hour following treatment initiation 1.

Fentanyl Sublingual Spray was evaluated and showed a Fatigue Modified Borg Score of -1.0 compared to 0.2 in patients with advanced cancers 3.

Tolvaptan was investigated as an intervention for this patient population 2.

Recent results — preliminary, needs further review

  • LY2606368 was evaluated regarding the incidence of Grade 4 treatment-related toxicity (5, 7, and 7 cases reported) 4.
  • Dexamethasone was studied for its impact on Edmonton Symptom Assessment System Dyspnea scores and Dyspnea Numeric Rating Scores 5.
  • Fentanyl Buccal Tablet and Fentanyl Pectin Nasal Spray were evaluated regarding Walk Distance at 6 Minutes [6, 7].
  • Other interventions including Azacitidine 8, Cisplatin 9, Vapotherm 10, Fentanyl 11, and Thalidomide 12 were investigated in Phase 2 trials.

For the clinician treating this condition

  • Fentanyl Nasal Spray is an established non-inferior alternative to intravenous opioids for rapid pain intensity reduction (NRS) at the one-hour mark 1.
  • Fentanyl Sublingual Spray showed a favorable profile regarding Fatigue Modified Borg Scores compared to control groups 3.

AI synthesis of 10 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors
Oncology Meta-analysis
Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors Cancer Patients Live Longer When Immunotherapy Starts Early in Day
This systematic review and meta-analysis evaluated 6129 patients with advanced solid tumors receiving immune checkpoint inhibitors. Earlier …
• Morning immunotherapy shots link to longer survival for advanced cancers • Helps patients fighting lung stomach kidney and other tough can…
May 5, 2026